Jazz Pharmaceuticals plc 2025-2026 Proxy Voting Records

Description as filed by funds: To elect four nominees for director named below to hold office until the 2028 Annual General Meeting of Shareholders: Jennifer E. Cook

Jazz Pharmaceuticals plc’s own tally for this item (“Elect Director: Jennifer E. Cook”): 49,838,761 for, 1,472,373 against, per its Form 8-K filed July 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the four nominees for director was elected as follows:”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 129 asset managers below reported 23,827,473 for, 221,758 against, 11,084 abstained.

Showing the 25 largest of 129 asset managers. See all 129 in the interactive database.

Description as filed by funds: To elect four nominees for director named below to hold office until the 2028 Annual General Meeting of Shareholders: Norbert G. Riedel, Ph.D.

Jazz Pharmaceuticals plc’s own tally for this item (“Elect Director: Norbert G. Riedel, Ph.D.”): 46,521,583 for, 4,787,903 against, per its Form 8-K filed July 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the four nominees for director was elected as follows:”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 129 asset managers below reported 22,718,415 for, 1,330,816 against, 11,084 abstained.

Showing the 25 largest of 129 asset managers. See all 129 in the interactive database.

Description as filed by funds: To elect four nominees for director named below to hold office until the 2028 Annual General Meeting of Shareholders: Patrick G. Enright

Jazz Pharmaceuticals plc’s own tally for this item (“Elect Director: Patrick G. Enright”): 49,122,808 for, 2,186,963 against, per its Form 8-K filed July 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the four nominees for director was elected as follows:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 129 asset managers below reported 23,809,544 for, 239,687 against, 11,084 abstained.

Showing the 25 largest of 129 asset managers. See all 129 in the interactive database.

Description as filed by funds: To elect four nominees for director named below to hold office until the 2028 Annual General Meeting of Shareholders: Seamus Mulligan

Jazz Pharmaceuticals plc’s own tally for this item (“Elect Director: Seamus Mulligan”): 49,488,355 for, 1,821,942 against, per its Form 8-K filed July 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the four nominees for director was elected as follows:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 129 asset managers below reported 23,936,413 for, 112,818 against, 11,084 abstained.

Showing the 25 largest of 129 asset managers. See all 129 in the interactive database.

Description as filed by funds: To grant the Board of Directors authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders. pursuant to the statutory pre-emption right that would otherwise apply.

Jazz Pharmaceuticals plc’s own tally for this item (“4. To grant our board of directors authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right t”): 53,607,244 for, 2,159,201 against — passed, per its Form 8-K filed July 25, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “This proposal was approved as follows:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Jazz Pharmaceuticals plc’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Authorize Issue of Equity without Pre-emptive Rights” (4 managers, 1,450,797 for).

The 127 asset managers below reported 22,558,000 for, 81,518 against.

Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive officers as disclosed in the proxy statement.

Jazz Pharmaceuticals plc’s own tally for this item (“3. To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement”): 48,261,149 for, 2,887,574 against — passed, per its Form 8-K filed July 25, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “This proposal was approved as follows:”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 128 managers: 23,696,663 for, 352,713 against, 11,084 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 447 managers: 28,156,169 for, 2,182,523 against, 148,326 abstained, 2,430 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify, on a non-binding advisory basis, the appointment of KPMG as the independent auditors of Jazz Pharmaceuticals plc for the fiscal year ending December 31, 2025 and to authorize, in a binding vote, the Board of Directors, acting through the audit committee, to determine KPMG's remuneration.

Jazz Pharmaceuticals plc’s own tally for this item (“2. To ratify, on a non-binding advisory basis, the appointment of KPMG, Dublin as our independent auditors for the fiscal year ending December 31, 2025 and to authorize, in a binding vote, our board of directors, acting ”): 54,773,976 for, 996,901 against — passed, per its Form 8-K filed July 25, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “This proposal was approved as follows:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 131 asset managers below reported 23,968,052 for, 126,868 against, 11,084 abstained.

Showing the 25 largest of 131 asset managers. See all 131 in the interactive database.